Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clene (CLNN) Other Non-Current Liabilities (2021 - 2025)

Clene has reported Other Non-Current Liabilities over the past 5 years, most recently at $5.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $5.1 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $5.1 million (changed N/A YoY), and the annual figure for FY2025 was $5.1 million, changed.
  • Other Non-Current Liabilities for Q4 2025 was $5.1 million at Clene, up from $4.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for CLNN hit a ceiling of $69.0 million in Q2 2021 and a floor of $10000.0 in Q4 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $1.9 million (2023), compared with a mean of $7.9 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 98.36% in 2023 and later surged 9131.82% in 2025.
  • Clene's Other Non-Current Liabilities stood at $2.3 million in 2021, then soared by 393.66% to $11.4 million in 2022, then plummeted by 99.91% to $10000.0 in 2023, then soared by 120.0% to $22000.0 in 2024, then skyrocketed by 22913.64% to $5.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $5.1 million (Q4 2025), $4.3 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.